Histopathological spectrum of lower Gastro-intestinal colonoscopic biopsy lesion with special reference to Her-2/neu expression in carcinoma colon

Abstract

Cancer associated with colon is one of the principal risk factors from decease in women and men. Although importance growing aspect of human epidermis receptor2 (Her2) as a therapeutic target is rising its role as a biomarker in the form of predicting indicator within colorectal Cancer (CRC)is still a mystery. Present research is undertaken for evaluating the Her2/neu description in Cancer of the colon. This research comprises 256patientswith spectrum of histopathological treatment ranging from colitis to colorectal carcinoma at our department between 2015- 2017. Her2/neu Immunohistochemistry was done in the colorectal carcinoma and scores based on Ruschoff et al. Her-2 testing in gastric cancer. Out of a total number of 256 cases enrolled in our study group, the majority belonged to the age group of 40-60 years, with M: F ratio being 1.4:1. The commonest site of the lesion occurred in the rectum (43.75%) followed by ascending colon and caecum (12.08%). Non neoplastic lesions constituted about two third of all cases, the commonest being inflammatory bowel disease(21.48%). In benign neoplastic lesions of tubular adenoma was the commonest type, and in malignant commonest type was colorectal adenocarcinoma NOS(64.44%) followed by mucinous adenocarcinoma (22.22%). Because of more prominent membranous staining observed in high grade colorectal cancers, Her2neu expression is found to be an important predictive marker of carcinoma colon, especially the adenocarcinoma, NOS. Like Breast carcinoma, target oriented therapy can be instituted especially in Her 2/neu positive high grade and metastatic tumors.